S Weller

Summary

Affiliation: Glaxo Wellcome
Country: USA

Publications

  1. ncbi Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects
    S Weller
    Worldwide Clinical Pharmacology, Glaxo Wellcome Inc, Research Triangle Park, North Carolina 27709, USA
    Antimicrob Agents Chemother 44:2052-60. 2000

Detail Information

Publications1

  1. ncbi Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects
    S Weller
    Worldwide Clinical Pharmacology, Glaxo Wellcome Inc, Research Triangle Park, North Carolina 27709, USA
    Antimicrob Agents Chemother 44:2052-60. 2000
    ..In conclusion, pharmacodynamic modeling supports the selection of abacavir 300 mg twice-daily dosing...